Phosphorylated mTOR expression correlates with poor outcome in early-stage triple negative breast carcinomas |
| |
| Authors: | Shir-Hwa Ueng Shin-Cheh Chen Yu-Sun Chang Swei Hsueh Yung-Chang Lin Hui-Ping Chien Yun-Feng Lo Shih-Che Shen Chuen Hsueh |
| |
| Affiliation: | 1Department of Pathology, Chang Gung Memorial Hospital, Linko, Taiwan;2Department of Surgery, Chang Gung Memorial Hospital, Taipei, Taiwan;3Chang Gung Molecular Medicine Research Center and Graduate Institute of Basic Medical Sciences, Taiwan;4Department of Oncology, Chang Gung Memorial Hospital, Linko, Taiwan;5Department of Pathology, Chang Gung Memorial Hospital, Keelong, Chang Gung University College of Medicine, Taoyuan, Taiwan |
| |
| Abstract: | The mammalian target of rapamycin (mTOR) plays an important role in cell growth, proliferation, and metabolism. Some studies have associated phosphorylated mTOR (p-mTOR) expression with worse outcome in breast cancers. However, the significance of p-mTOR expression specifically in triple negative breast carcinoma (TNBC) is unknown. In this study, p-mTOR expression was evaluated by immunohistochemistry in 172 TNBCs and the result was correlated with clinicopathologic variables and disease outcome. The majority of tumors (72.1%) were p-mTOR positive; p-mTOR expression did not correlate with age, tumor size, grade, lymph node status, or tumor stage. In patients at stage 1 and 2 disease, those with p-mTOR expression had significantly worse overall as well as recurrence-free survival compared to those without p-mTOR expression. p-mTOR expression appears to be an adverse prognostic indicator in early-stage TNBCs. The assessment of p-mTOR expression in these tumors may also help to stratify patients for future target therapy studies. |
| |
| Keywords: | Phosphorylated mammalian target of rapamycin (p-mTOR) triple negative breast cancer |
|
|
